Patents by Inventor Akira Shimamoto

Akira Shimamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8809296
    Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: August 19, 2014
    Assignee: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Publication number: 20140179769
    Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.
    Type: Application
    Filed: February 26, 2014
    Publication date: June 26, 2014
    Applicant: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Patent number: 8703930
    Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: April 22, 2014
    Assignee: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi
  • Publication number: 20140064174
    Abstract: A wireless communication system includes a user terminal capable of discontinuous reception (DRX) and a base station communicating with the user terminal. The user terminal includes a receiving section for receiving information about DRX from the base station; a DRX cycle setting section for setting DRX cycles; a first period setting section for setting a first period among the DRX cycles to receive a downlink signal; and a receivable period setting section for setting a receivable period to receive the downlink signal within a second period outside of the first period. The base station includes a DRX cycle setting section for setting the DRX cycles; a first period setting section for setting the first period; a receivable period setting section for setting the receivable period; and a transmission section for transmitting the set information to the user terminal to be set on the user terminal.
    Type: Application
    Filed: November 13, 2013
    Publication date: March 6, 2014
    Applicant: FUJITSU LIMITED
    Inventors: Masahiro ABE, Akira SHIMAMOTO, Takato EZAKI
  • Publication number: 20130245097
    Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.
    Type: Application
    Filed: May 22, 2013
    Publication date: September 19, 2013
    Applicant: GENECARE RESEARCH INSTITUTE CO., LTD.
    Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi
  • Patent number: 8470798
    Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: June 25, 2013
    Assignee: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi
  • Patent number: 8314073
    Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.
    Type: Grant
    Filed: November 17, 2005
    Date of Patent: November 20, 2012
    Assignee: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Patent number: 8299044
    Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: October 30, 2012
    Assignee: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Publication number: 20120225928
    Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.
    Type: Application
    Filed: May 16, 2012
    Publication date: September 6, 2012
    Applicant: Genecare Research Instiute Co., Ltd.
    Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi
  • Patent number: 8193332
    Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: June 5, 2012
    Assignee: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi
  • Publication number: 20100168209
    Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.
    Type: Application
    Filed: December 21, 2009
    Publication date: July 1, 2010
    Applicant: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Publication number: 20090215867
    Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.
    Type: Application
    Filed: November 17, 2005
    Publication date: August 27, 2009
    Applicant: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Publication number: 20090028861
    Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.
    Type: Application
    Filed: April 8, 2005
    Publication date: January 29, 2009
    Applicant: Genecare Research Institute Co., Ltd.
    Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi
  • Patent number: 7329497
    Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: February 12, 2008
    Assignee: Agene Research Institute Co., Ltd.
    Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
  • Publication number: 20070243570
    Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.
    Type: Application
    Filed: May 19, 2004
    Publication date: October 18, 2007
    Applicant: Genecare Research Institute Co., Ltd
    Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
  • Publication number: 20060240470
    Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.
    Type: Application
    Filed: June 30, 2006
    Publication date: October 26, 2006
    Applicant: Agene Research Institute Co., Ltd.
    Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
  • Publication number: 20060188928
    Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.
    Type: Application
    Filed: May 2, 2006
    Publication date: August 24, 2006
    Applicant: Agene Research Institute Co., Ltd.
    Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
  • Patent number: 7081522
    Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: July 25, 2006
    Assignee: Agene Research Institute Co., Ltd.
    Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
  • Publication number: 20040259147
    Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.
    Type: Application
    Filed: July 2, 2004
    Publication date: December 23, 2004
    Applicant: Agene Research Institute Co., Ltd.
    Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
  • Publication number: 20040224312
    Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.
    Type: Application
    Filed: December 31, 2001
    Publication date: November 11, 2004
    Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi